Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

EAGAN, Minn., May 31, 2017 (GLOBE NEWSWIRE) — Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1™, the company’s ongoing Phase 2 clinical trial in advanced melanoma/triple negative breast cancer, will be presented at the 2017 ASCO Annual Meeting, taking place in Chicago, IL, June 2-6, 2017. The ASCO presentation details are as follows:

Session Date & Time: Monday, June 5, 2017, 8:00 AM – 11:30 AM Central Time
Session: Developmental Therapeutics—Immunotherapy
Presentation Title: A multicenter, open-label, phase II study of PGG beta-glucan and pembrolizumab in patients (pts) with advanced melanoma (MEL) following progression on treatment with checkpoint inhibitors (CPI) or triple negative breast cancer (TNBC) failing front-line chemotherapy for metastatic disease.
Session Location: McCormick Place, Hall A, Poster Board #193a
Abstract No.: TPS3105

Biothera announced earlier this year initiation of patient dosing in the Phase 2 study, which is evaluating the Company’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada). The multi-center, open-label study is anticipated to enroll up to 71 patients who have tested positive for a biomarker that may identify patients with higher probability of responding to Imprime PGG combination therapy.  Additional information on the trial is available by visiting

About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies.  Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has demonstrated a favorable safety profile in more than 400 subjects and signals of activity in multiple combinations and tumor types.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.


CONTACT: Contact:
David Walsh
Biothera Pharmaceuticals, Inc.